```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
REP G1=(0-7) CH
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   5
NUMBER OF NODES IS  21

STEREO ATTRIBUTES: NONE


=> s l1 ful
FULL SEARCH INITIATED 11:35:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1339 TO ITERATE

100.0% PROCESSED    1339 ITERATIONS                                  44 ANSWERS
SEARCH TIME: 00.00.01

L3            44 SEA SSS FUL L1

=> d scan

L3   44 ANSWERS   REGISTRY  COPYRIGHT 2005 ACS on STN
IN   2,5-Pyrrolidinedione, 1-[2-[4-[[[(3R,4S)-4-[4-[3-[(2-
     fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]et
     hyl]-, rel- (9CI)
MF   C34 H40 F N3 O5

Relative stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):43

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Naphthalenecarboxylic acid, 6-[[[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester (9CI)
MF C34 H37 F N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 7-Quinolinemethanamine, N-[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI)
MF C32 H37 N3 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Pyrrolidinone, 1-[2-[4-[[[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]ethyl]-, rel- (9CI)
MF C34 H42 F N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Naphthalenecarboxylic acid, 6-[[[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]- (9CI)
MF C33 H35 F N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 7-Quinolinemethanamine, 1,2,3,4-tetrahydro-N-[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI)
MF C32 H41 N3 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetamide, 3,4-dihydro-7-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-N,N-dimethyl-, rel- (9CI)
MF C36 H48 N4 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, 4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C29 H31 F5 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, 4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-methyl-N-(2-naphthalenylmethyl)-, (3R,4S)-rel- (9CI)
MF C34 H40 N2 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, 4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-(2-naphthalenylmethyl)- (9CI)
MF C33 H38 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, [4-[[[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]-, methyl ester (9CI)
MF C31 H37 F N2 O5





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Naphthalenol, 6-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, rel- (9CI)
MF C33 H38 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, N-[(6-methoxy-2-naphthalenyl)methyl]-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]- (9CI)
MF C34 H40 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2,5-Pyrrolidinedione, 1-[2-[4-[[[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]ethyl]- (9CI)
MF C34 H40 F N3 O5

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, N-(5-benzofuranylmethyl)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-, (3R,4S)-rel- (9CI)
MF C31 H36 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 7-Quinolinemethanamine, N-[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]- (9CI)
MF C32 H37 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Pyrrolidinone, 1-[2-[4-[[[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]ethyl]- (9CI)
MF C34 H42 F N3 O4

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Indole-5-methanamine, N-[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI)
MF C31 H37 N3 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 7-Quinolinemethanamine, 1,2,3,4-tetrahydro-N-[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]- (9CI)
MF C32 H41 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetamide, 3,4-dihydro-7-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-N,N-dimethyl- (9CI)
MF C36 H48 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester, rel- (9CI)

MF C35 H40 N2 O5

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, 4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-methyl-N-(2-naphthalenylmethyl)- (9CI)
MF C34 H40 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, N-([1,1'-biphenyl]-4-ylmethyl)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-, (3R,4S)-rel- (9CI)
MF C35 H40 N2 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, rel- (9CI)
MF C34 H38 N2 O5

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Naphthalenol, 6-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]- (9CI)
MF C33 H38 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,2-Ethanedisulfonic acid, compd. with rel-(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-(2-naphthalenylmethyl)-3-piperidinamine (1:1) (9CI)
MF C33 H38 N2 O3 . C2 H6 O6 S2

CM 1

Relative stereochemistry.



CM 2



L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester, rel- (9CI)
MF C35 H40 N2 O5

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, N-(5-benzofuranylmethyl)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]- (9CI)
MF C31 H36 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI)
MF C25 H28 N2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 7-Quinolinemethanamine, N-[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI)
MF C31 H34 F N3 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Indole-5-methanamine, N-[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]- (9CI)
MF C31 H37 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl-, hydrochloride (9CI)
MF C25 H28 N2 O . x Cl H



●x HCl

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester, rel- (9CI)
MF C34 H37 F N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Naphthalenecarboxylic acid, 6-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester (9CI)

MF C35 H40 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Piperidinone, 5-[[(2-methoxyphenyl)methyl]amino]-4,6-diphenyl- (9CI)
MF C25 H26 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, rel- (9CI)
MF C33 H35 F N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Naphthalenecarboxylic acid, 6-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]- (9CI)
MF C34 H38 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, N-[(5-chloro-2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI)
MF C25 H27 Cl N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, 4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-, (3R,4S)-rel- (9CI)
MF C29 H31 F5 N2 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Naphthalenecarboxylic acid, 6-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester (9CI)
MF C35 H40 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 3-Piperidinamine, 4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-(2-naphthalenylmethyl)-, (3R,4S)-rel- (9CI)
MF C33 H38 N2 O3
CI COM

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, [4-[[[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]-, methyl ester, rel- (9CI)
MF C31 H37 F N2 O5

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 7-Quinolinemethanamine, N-[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]- (9CI)

MF C31 H34 F N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 44 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinamine, N-[(6-methoxy-2-naphthalenyl)methyl]-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-, (3R,4S)-rel- (9CI)
MF C34 H40 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	168.76	168.97

FILE 'CAPLUS' ENTERED AT 11:37:17 ON 17 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Feb 2005 VOL 142 ISS 8
FILE LAST UPDATED: 16 Feb 2005 (20050216/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 19 L3

=> d bib abs hitstr 1-19

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:1043341 CAPLUS
DN 142:106555
TI The discovery and preparation of disubstituted novel amino-aryl-piperidine-based renin inhibitors
AU Cody, Wayne L.; Holsworth, Daniel D.; Powell, Noel A.; Jalaie, Mehran; Zhang, Erli; Wang, Wei; Samas, Brian; Bryant, John; Ostroski, Robert; Ryan, Michael J.; Edmunds, Jeremy J.
CS Department of Chemistry, Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI, 48105, USA
SO Bioorganic & Medicinal Chemistry (2004), Volume Date 2005, 13(1), 59-68
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
AB Recently, trans-disubstituted oxo-aryl-piperidines have been identified as small mol. nonpeptide renin inhibitors for the modulation of hypertension. Herein, the authors report on the discovery and preparation of a new class of novel cis-disubstituted amino-aryl-piperidines as a mixture of enantiomers that are potent in vitro renin inhibitors and also, possess in vivo antihypertensive activity in a double transgenic mouse model.
IT **773092-07-2P 773092-08-3P 773092-09-4P**
773092-10-7P 773092-13-0P 773092-14-1P
773092-15-2P 773092-16-3P 821771-65-7P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(discovery and preparation of disubstituted amino-aryl-piperidine-based renin inhibitors)
RN 773092-07-2 CAPLUS
CN 3-Piperidinamine, 4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-(2-naphthalenylmethyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-08-3 CAPLUS
CN 3-Piperidinamine, N-[(6-methoxy-2-naphthalenyl)methyl]-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-09-4 CAPLUS
CN 7-Quinolinemethanamine, N-[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-10-7 CAPLUS
CN 7-Quinolinemethanamine, 1,2,3,4-tetrahydro-N-[(3R,4S)-4-[4-[3-[(2-

methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-13-0 CAPLUS
CN 3-Piperidinamine, N-(5-benzofuranylmethyl)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-14-1 CAPLUS
CN 1H-Indole-5-methanamine, N-[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-15-2 CAPLUS
CN 1-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-16-3 CAPLUS
CN 1-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 821771-65-7 CAPLUS
CN 3-Piperidinamine, N-([1,1'-biphenyl]-4-ylmethyl)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **821771-66-8**
RL: PRP (Properties)
(discovery and preparation of disubstituted amino-aryl-piperidine-based renin inhibitors)
RN 821771-66-8 CAPLUS
CN 1,2-Ethanedisulfonic acid, compd. with rel-(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-(2-naphthalenylmethyl)-3-piperidinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 773092-07-2
CMF C33 H38 N2 O3

Relative stereochemistry.



CM 2

CRN 110-04-3
CMF C2 H6 O6 S2



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:995777 CAPLUS

DN 141:406121
TI New pharmaceutical combinations of nitric oxide synthase inhibitors and NK-1 receptor antagonists and selective serotonin reuptake inhibitors for treatment of disorders facilitated by altering circadian rhythms
IN Saltarelli, Mario David; Lowe, John Adams
PA Pfizer Inc, USA
SO U.S. Pat. Appl. Publ., 59 pp., Division of U.S. Ser. No. 572,619.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004229911	A1	20041118	US 2004-867123	20040614
PRAI	US 2000-572619	A3	20000517		

OS MARPAT 141:406121
AB The present invention relates to new pharmaceutical uses for compds. that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI (selective serotonin reuptake inhibitor) or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.
IT **136871-15-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new pharmaceutical combinations of nitric oxide synthase inhibitors and NK-1 receptor antagonists and selective serotonin reuptake inhibitors for treatment of disorders facilitated by altering circadian rhythms)
RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:857185 CAPLUS
DN 141:332059
TI Preparation of disubstituted piperidine derivatives as renin inhibitors
IN Cody, Wayne Livingston; Edmunds, Jeremy John; Holsworth, Daniel Dale; Powell, Noel Aaron
PA USA
SO U.S. Pat. Appl. Publ., 40 pp.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004204455	A1	20041014	US 2004-811200	20040326
	WO 2004089903	A1	20041021	WO 2004-IB1162	20040401

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-461962P P 20030410
US 2004-542279P P 20040209

OS MARPAT 141:332059

GI



I



II

AB Title compds. I [R1-2 = H, (un)substituted alkyl; R3 = H, oxo, thioxo; R0 = H, (un)substituted alkyl provided that when R3 = (thi)oxo, R0 is absent; R4-7 = H, halo, carboxy, etc.; Q = (un)substituted amino, etc.; T = (un)substituted (hetero)aryl, alkyl; W = absent, (un)substituted aryl, heteroaryl; Z = (alkyl)cycloalkylene, (alkyl)heterocycloalkylene, etc.] are prepared For instance, II was prepared in 4 steps from 3-hydroxy-4-(4-hydroxyphenyl)piperidine-1-carboxylic acid tert-Bu ester and 1-(3-iodopropoxymethyl)-2-methoxybenzene. Renin IC50 for II = 0.087 μM. I are useful for the treatment of, e.g., hypertension, congestive heart failure, etc.

IT **773092-07-2P 773092-08-3P 773092-09-4P**
773092-10-7P 773092-11-8P 773092-12-9P
773092-13-0P 773092-14-1P 773092-15-2P
773092-16-3P 773092-18-5P 773092-19-6P
773092-20-9P 773092-21-0P 773092-24-3P
773092-25-4P 773092-26-5P 773092-27-6P
773092-29-8P 773092-30-1P 773092-31-2P
773092-32-3P 773092-33-4P 773092-34-5P
773092-35-6P 773092-36-7P 773092-37-8P
773092-38-9P 773092-39-0P 773092-41-4P
773092-42-5P 773092-43-6P 773092-44-7P

773092-47-0P 773092-48-1P 773092-49-2P
773092-50-5P 773092-52-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of disubstituted piperidine derivs. as renin inhibitors for the treatment of, e.g., hypertension and glaucoma)

RN 773092-07-2 CAPLUS
CN 3-Piperidinamine, 4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-(2-naphthalenylmethyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-08-3 CAPLUS
CN 3-Piperidinamine, N-[(6-methoxy-2-naphthalenyl)methyl]-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-09-4 CAPLUS
CN 7-Quinolinemethanamine, N-[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-10-7 CAPLUS
CN 7-Quinolinemethanamine, 1,2,3,4-tetrahydro-N-[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-11-8 CAPLUS
CN 3-Piperidinamine, 4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-methyl-N-(2-naphthalenylmethyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-12-9 CAPLUS
CN 2-Naphthalenol, 6-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-13-0 CAPLUS
CN 3-Piperidinamine, N-(5-benzofuranylmethyl)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-14-1 CAPLUS
CN 1H-Indole-5-methanamine, N-[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-15-2 CAPLUS
CN 1-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-16-3 CAPLUS
CN 1-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-18-5 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-19-6 CAPLUS
CN 7-Quinolinemethanamine, N-[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-20-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-21-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[[[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-24-3 CAPLUS
CN 3-Piperidinamine, 4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-25-4 CAPLUS
CN Acetic acid, [4-[[[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-26-5 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[2-[4-[[[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-27-6 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[4-[[[(3R,4S)-4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-29-8 CAPLUS
CN 1(2H)-Quinolineacetamide, 3,4-dihydro-7-[[[(3R,4S)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773092-30-1 CAPLUS
CN 3-Piperidinamine, 4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 773092-31-2 CAPLUS
CN 3-Piperidinamine, N-[(6-methoxy-2-naphthalenyl)methyl]-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 773092-32-3 CAPLUS
CN 7-Quinolinemethanamine, N-[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 773092-33-4 CAPLUS
CN 7-Quinolinemethanamine, 1,2,3,4-tetrahydro-N-[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 773092-34-5 CAPLUS
CN 3-Piperidinamine, 4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-N-methyl-N-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 773092-35-6 CAPLUS
CN 2-Naphthalenol, 6-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 773092-36-7 CAPLUS
CN 3-Piperidinamine, N-(5-benzofuranylmethyl)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 773092-37-8 CAPLUS
CN 1H-Indole-5-methanamine, N-[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 773092-38-9 CAPLUS
CN 1-Naphthalenecarboxylic acid, 6-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 773092-39-0 CAPLUS
CN 1-Naphthalenecarboxylic acid, 6-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 773092-41-4 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 773092-42-5 CAPLUS
CN 7-Quinolinemethanamine, N-[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 773092-43-6 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[[[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 773092-44-7 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[[[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 773092-47-0 CAPLUS
CN 3-Piperidinamine, 4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 773092-48-1 CAPLUS
CN Acetic acid, [4-[[[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)





RN 773092-49-2 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[2-[4-[[[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



PAGE 2-A



RN 773092-50-5 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[4-[[[4-[4-[3-[(2-fluorophenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 773092-52-7 CAPLUS
CN 1(2H)-Quinolineacetamide, 3,4-dihydro-7-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]amino]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:97302 CAPLUS
DN 138:131154
TI Use of NK-1 receptor antagonists to modify unwanted anxiety behavior in dogs, cats and horses
IN Bronk, Brian Scott; Hickman, Mary Anne; Kilroy, Carolyn Rose
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003009848	A1	20030206	WO 2002-IB2847	20020715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	NZ 529606	A	20031219	NZ 2002-529606	20020715
	EP 1411946	A1	20040428	EP 2002-745741	20020715
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005504029	T2	20050210	JP 2003-515240	20020715
	US 2003139443	A1	20030724	US 2002-199284	20020719
PRAI	US 2001-306692P	P	20010720		
	WO 2002-IB2847	W	20020715		

AB The invention discloses a method for treating abnormal anxiety behavior in companion animals comprising administering to a companion animal in need thereof a therapeutically effective amount of an NK-1 receptor antagonist.
IT **136871-15-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonists to modify unwanted anxiety behavior in companion animals)
RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:841966 CAPLUS
DN 134:13350
TI Nitric oxide synthase (NOS) inhibitor combinations with other agents for treatment of disorders treatable by altering circadian rhythm
IN Saltarelli, Mario David; Lowe, John Adams, III
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000071107	A2	20001130	WO 2000-IB295	20000316
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2374668	AA	20001130	CA 2000-2374668	20000316
	EP 1178784	A1	20020213	EP 2000-907891	20000316
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000010820	A	20020305	BR 2000-10820	20000316
	TR 200103351	T2	20020621	TR 2001-200103351	20000316
	EE 200100611	A	20030217	EE 2001-611	20000316
	JP 2003523941	T2	20030812	JP 2000-619414	20000316
	NO 2001005651	A	20020118	NO 2001-5651	20011120
	HR 2001000862	A1	20030630	HR 2001-862	20011120
	ZA 2001009555	A	20040407	ZA 2001-9555	20011120
	BG 106208	A	20020930	BG 2001-106208	20011211
PRAI	US 1999-135520P	P	19990521		
	WO 2000-IB295	W	20000316		

AB New pharmaceutical uses are provided for compds. that exhibit activity as NOS inhibitors. Specifically, the invention provides the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either a selective serotonin reuptake inhibitor (SSRI) or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders

associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

IT **136871-15-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitric oxide synthase inhibitor combinations with other agents for treatment of disorders treatable by altering circadian rhythm)

RN 136871-15-3 CAPLUS

CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:416752 CAPLUS

DN 127:29079

TI NK-1 receptor antagonists for the treatment of cancer

IN Howard, Harry R.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 773026	A2	19970514	EP 1996-308039	19961106
	EP 773026	A3	19991117		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1154240	A	19970716	CN 1996-122019	19961024
	CA 2189501	AA	19970507	CA 1996-2189501	19961104
	AU 9670592	A1	19970515	AU 1996-70592	19961105
	AU 700520	B2	19990107		
	ZA 9609285	A	19980505	ZA 1996-9285	19961105
	US 5990125	A	19991123	US 1997-786128	19970117
	US 6194436	B1	20010227	US 1999-334369	19990616
PRAI	US 1995-7275P	P	19951106		
	US 1996-10232P	P	19960119		
	US 1997-786128	A1	19970117		

OS MARPAT 127:29079

AB NK-1 receptor antagonists (e.g. Substance P receptor antagonists) (Markush included) are used for the manufacture of a medicament for the treatment of cancer in a mammal, particularly for the treatment of small cell lung carcinoma, APUDoma, astrocytoma, neuroendocrine tumor, or extrapulmonary small cell carcinoma.

IT **136871-15-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Nk-1 receptor antagonists for the treatment of cancer)

RN 136871-15-3 CAPLUS

CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA

INDEX NAME)



L4 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:389101 CAPLUS
DN 127:13461
TI Antiemetic composition containing an NK-1 receptor antagonist
IN Gonsalves, Susan F.; Watson, John W.; Silberman, Sandra L.
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 769300	A2	19970423	EP 1996-307533	19961017
	EP 769300	A3	19991124		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	TW 458774	B	20011011	TW 1996-85108626	19960716
	IL 119418	A1	20010724	IL 1996-119418	19961014
	CN 1151893	A	19970618	CN 1996-112447	19961017
	JP 09110721	A2	19970228	JP 1996-297370	19961018
	CA 2188227	AA	19970421	CA 1996-2188227	19961018
	CA 2188227	C	20000808		
	AU 9670279	A1	19970515	AU 1996-70279	19961018
	AU 700841	B2	19990114		
	ZA 9608790	A	19980420	ZA 1996-8790	19961018
	NZ 299606	A	20000728	NZ 1996-299606	19961018
PRAI	US 1995-5728P	P	19951020		

GI



I

AB Methods are disclosed for treating or preventing emesis in mammals, including humans, using an NK-1 antagonist in combination with one or more other active agents selected from (a) a glucocorticoid or corticosteroid, (b) a benzodiazepine, (c) metaclopramide and (d) an intracellular mol. scavenger.

IT **136871-15-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiemetic composition with NK-1 receptor antagonist and other agent)

RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:356537 CAPLUS
DN 126:325515
TI NK-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
IN Piedimonte, Giovanni; Hess, Hans J.; Lowe, John A., III
PA Pfizer Inc., USA; Piedimonte, Giovanni; Hess, Hans, J.; Lowe, John, A., Iii
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9713514	A1	19970417	WO 1996-IB1042	19961002
	W: CA, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2228572	AA	19970417	CA 1996-2228572	19961002
	CA 2228572	C	20030722		
	EP 854720	A1	19980729	EP 1996-931199	19961002
	EP 854720	B1	19990804		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	AT 182788	E	19990815	AT 1996-931199	19961002
	ES 2134639	T3	19991001	ES 1996-931199	19961002
	JP 3041051	B2	20000515	JP 1997-514868	19961002
	JP 10511119	T2	19981027		
	US 6562335	B1	20030513	US 1998-77045	19980518
	GR 3031758	T3	20000229	GR 1999-402849	19991104
PRAI	US 1995-5002P	P	19951010		
	US 1995-6344P	P	19951107		
	WO 1996-IB1042	W	19961002		

AB The present invention relates to a method of preventing or treating the neurogenic inflammation associated with the use of viral vectors in gene therapy in a mammal, including a human, by administering to the mammal an NK-1 receptor antagonist (e.g., a substance P receptor antagonist).
IT **136871-15-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy)
RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:551261 CAPLUS
DN 125:185903
TI NK-1 receptor antagonists for the treatment of neuronal injury and stroke
IN Lowe, John A., III; Nelson, Robert B.
PA Pfizer Inc., USA
SO Can. Pat. Appl., 148 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2164804	AA	19960613	CA 1995-2164804	19951208
	CA 2164804	C	19990727		
	IL 116249	A1	20030706	IL 1995-116249	19951204
	AT 260656	E	20040315	AT 1995-308876	19951207
	PT 721778	T	20040730	PT 1995-308876	19951207
	ES 2217274	T3	20041101	ES 1995-308876	19951207
	AU 9540304	A1	19960620	AU 1995-40304	19951208
	AU 719159	B2	20000504		
	CN 1132072	A	19961002	CN 1995-120596	19951208
	NZ 280627	A	20000623	NZ 1995-280627	19951208
	KR 195651	B1	19990615	KR 1995-48062	19951209
	ZA 9510483	A	19970609	ZA 1995-10483	19951211
	JP 08239323	A2	19960917	JP 1995-323355	19951212
	US 6376507	B1	20020423	US 1998-99289	19980618
PRAI	US 1994-354702	A	19941212		

OS MARPAT 125:185903
AB Antagonists to NK-1 neurokinin receptors are useful for treating or preventing stroke, epilepsy, head trauma, spinal cord trauma, ischemic neuronal damage such as cerebral ischemic damage from stroke or vascular occlusion (e.g. during open heart surgery), excitotoxic neuronal damage (e.g. in stroke or epilepsy), and amyotrophic lateral sclerosis in mammals, including humans. The antagonists include certain quinuclidine, piperidine, pyrrolidine, azanorbornane, and ethylenediamine derivs. and related compds. that are substance P receptor antagonists (no data).
IT **136871-15-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonists for treatment of neuronal injury and stroke)
RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:534545 CAPLUS
DN 125:185901
TI NK-1 receptor antagonists for the treatment of neuronal injury and stroke
IN Lowe, John A., III; Nelson, Robert B.
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 75 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 721778	A2	19960717	EP 1995-308876	19951207
	EP 721778	A3	19991110		
	EP 721778	B1	20040303		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	IL 116249	A1	20030706	IL 1995-116249	19951204
	AT 260656	E	20040315	AT 1995-308876	19951207
	PT 721778	T	20040730	PT 1995-308876	19951207
	ES 2217274	T3	20041101	ES 1995-308876	19951207
	AU 9540304	A1	19960620	AU 1995-40304	19951208
	AU 719159	B2	20000504		
	CN 1132072	A	19961002	CN 1995-120596	19951208
	NZ 280627	A	20000623	NZ 1995-280627	19951208
	KR 195651	B1	19990615	KR 1995-48062	19951209
	ZA 9510483	A	19970609	ZA 1995-10483	19951211
	JP 08239323	A2	19960917	JP 1995-323355	19951212
	US 6376507	B1	20020423	US 1998-99289	19980618
PRAI	US 1994-354702	A	19941212		

OS MARPAT 125:185901

AB A method is provided for treating or preventing stroke, epilepsy, head trauma, spinal cord trauma, ischemic neuronal damage, such as cerebral ischemic damage from stroke or vascular occlusion (e.g., during open heart surgery), excitotoxic neuronal damage (e.g., in stroke or epilepsy) and amyotrophic lateral sclerosis in mammals, including humans, using an NK-1 antagonist. Also provided is a method of treating or preventing such disorders in mammals, including humans, using certain quinuclidine derivs., piperidine derivs., pyrrolidine derivs., azanorbornane derivs., ethylene diamine derivs. and related compds. that are substance P receptor antagonists.

IT **136871-15-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonists for the treatment of neuronal injury and stroke)

RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:464513 CAPLUS
DN 125:132779
TI NK-1 receptor antagonists and 5-HT3 receptor antagonists for the treatment of emesis
IN Gonsalves, Susan F.
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 715855	A2	19960612	EP 1995-308273	19951120
	EP 715855	A3	19990120		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5576317	A	19961119	US 1994-353049	19941209
	IL 116203	A1	20030731	IL 1995-116203	19951130
	JP 08225464	A2	19960903	JP 1995-339871	19951205
	JP 3372156	B2	20030127		
	CN 1132625	A	19961009	CN 1995-120539	19951205
	CN 1082371	B	20020410		
	CA 2164689	AA	19960610	CA 1995-2164689	19951207
	CA 2164689	C	19990316		
	AU 9540306	A1	19960620	AU 1995-40306	19951208
	AU 717776	B2	20000330		
	ZA 9510431	A	19970609	ZA 1995-10431	19951208
	KR 197452	B1	19990615	KR 1995-47841	19951208
PRAI	US 1994-353049	A	19941209		

AB A method is provided for treating or preventing emesis in a mammal, including a human, by administering a 5-HT3 receptor antagonist and an NK-1 receptor antagonist (e.g., a substance P receptor antagonist). Also provided are pharmaceutical compns. containing a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an NK-1 receptor antagonist. The 5-HT3 antagonist is e.g. ondansetron, tropisetron, or granisetron. More than one hundred NK-1 antagonists are claimed. The antiemetic activity of NK-1 antagonist (2S,3S)-3-methoxybenzylamino-2-phenylpiperidine, alone and in combination with ondansetron, was determined

IT **179117-96-5**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonists and 5-HT3 receptor antagonists for the treatment of emesis)

RN 179117-96-5 CAPLUS
CN 3-Piperidinamine, N-[(5-chloro-2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:462448 CAPLUS
DN 125:132804
TI NK-1 receptor antagonists for the treatment of eye disorders
IN Hess, Hans-Juergen Ernst
PA Pfizer Inc., USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9614845	A1	19960523	WO 1995-IB811	19950929
	W: CA, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2205016	AA	19960523	CA 1995-2205016	19950929
	EP 790825	A1	19970827	EP 1995-931373	19950929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10508837	T2	19980902	JP 1995-515865	19950929
PRAI	US 1994-336955	A	19941110		
	WO 1995-IB811	W	19950929		

OS MARPAT 125:132804
AB A method is disclosed for treating or preventing a disorder of the eye, selected from glaucoma, ocular hypertension, miosis, excess lacrimation, hyperemia, and breakdown of the blood aqueous barrier in mammals, including humans, using an NK-1 antagonist. Also disclosed is a method of treating or preventing such disorders in mammals, including humans, using certain quinuclidine derivs., piperidine derivs., pyrrolidine derivs., azanorbornane derivs., and ethylene diamine-derived and related compds. that are substance P receptor antagonists.
IT **136871-15-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonists for the treatment of eye disorders)
RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:808197 CAPLUS

DN 123:218418
TI Pharmaceutical agents for the inhibition of angiogenesis
IN Lowe, John A. Iii
PA Pfizer Inc., USA
SO Can. Pat. Appl., 151 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2136295	AA	19950524	CA 1994-2136295	19941121
	EP 659409	A2	19950628	EP 1994-202995	19941014
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
PRAI	US 1993-157493	A	19931123		

OS MARPAT 123:218418
AB The present invention relates to medicine for (a) inhibiting angiogenesis in mammals or (b) treating or preventing a disease or condition that is caused or mediated by angiogenesis or of which angiogenesis is a symptom in a mammal, using compds. that are substance P receptor antagonists and, specifically, certain quinuclidine derivs., piperidine derivs., pyrrolidine derivs., azanorbornane derivs., ethylenediamine derivs. and related compds.
IT **136871-15-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals for the inhibition of angiogenesis)
RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:667293 CAPLUS
DN 123:65828
TI Pharmaceuticals for treatment or prevention of sunburn.
IN Hess, Hans-Jurgen Ernst; Nagahisa, Atsushi
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 91 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 653208	A2	19950517	EP 1994-203210	19941103
	EP 653208	A3	19951011		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2135837	AA	19950518	CA 1994-2135837	19941115
PRAI	US 1993-153682	A	19931117		

OS MARPAT 123:65828
AB The present invention relates to the use of certain quinuclidine, piperidine, azanorbornane derivs. and related compds., for the manufacture of a

drug for the treatment or prevention of sunburn. The antisunburn activity of compds. that are substance P receptor antagonists was demonstrated in guinea pigs.

IT **136871-15-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals for treatment or prevention of sunburn)

RN 136871-15-3 CAPLUS

CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:648256 CAPLUS

DN 124:763

TI Substance P antagonists for treatment of disorders caused by Helicobacter pylori or other spiral urease-positive gram-negative bacteria

IN Clancy, Joanna

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 92 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 655246	A1	19950531	EP 1994-308480	19941116
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2136801	AA	19950531	CA 1994-2136801	19941128
	CA 2136801	C	19990223		
	US 5750535	A	19980512	US 1995-520522	19950829
PRAI	US 1993-159157	A	19931130		

OS MARPAT 124:763

AB Disorders caused by spiral urease-pos. gram-neg. bacteria such as H. pylori in mammals, including humans, are treated or prevented with substance P receptor antagonists, e.g. quinuclidines, piperidines, pyrrolidines, azanorbornanes, ethylenediamine derivs., etc. (Markush structures given) (no data).

IT **136871-15-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substance P antagonists for treatment of disorders caused by Helicobacter pylori or other spiral urease-pos. gram-neg. bacteria)

RN 136871-15-3 CAPLUS

CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:397278 CAPLUS
DN 122:178403
TI Substance P antagonists for the treatment of emesis
IN Desai, Manoj C.; Lowe, John A., III; Watson, John W.
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 93 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 627221	A2	19941207	EP 1994-303467	19940516
	EP 627221	A3	19950802		
	EP 627221	B1	20011128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5393762	A	19950228	US 1993-72629	19930604
	AT 209490	E	20011215	AT 1994-303467	19940516
	ES 2164088	T3	20020216	ES 1994-303467	19940516
	PT 627221	T	20020429	PT 1994-303467	19940516
	IL 109802	A1	20020421	IL 1994-109802	19940526
	JP 07053362	A2	19950228	JP 1994-121042	19940602
	CA 2124990	C	19990420	CA 1994-2124990	19940602
	AU 9464521	A1	19941215	AU 1994-64521	19940603
	AU 666077	B2	19960125		
	ZA 9403896	A	19951204	ZA 1994-3896	19940603
	HU 71550	A2	19951228	HU 1994-1676	19940603
	CN 1121806	A	19960508	CN 1994-106917	19940603
	CN 1100535	B	20030205		
	KR 190729	B1	19990601	KR 1994-12527	19940603
	RU 2135179	C1	19990827	RU 1994-20410	19940603
	NZ 260674	A	20000728	NZ 1994-260674	19940603
PRAI	US 1993-72629	A	19930604		

OS MARPAT 122:178403
AB Quinuclidine derivs., piperidine derivs., azanorbornane derivs., and related compds. (Markush included) are disclosed for treating or preventing emesis in mammals, including humans. The compound cis-3-[(2-methoxyphenyl)methylamino]-2-benzhydrylquinuclidine inhibited cisplatinum-induced emesis in ferrets when administered at a dose of 10 mg/kg s.c., 30 min before cisplatinum exposure.
IT **136871-15-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(quinuclidine derivs., piperidine derivs., azanorbornane derivs., and related compds. as substance P antagonists for the treatment of emesis)
RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:595919 CAPLUS
DN 121:195919
TI Pharmaceutical agents for treatment of urinary incontinence
IN Desai, Manoj C.; Lowe, Iii John A.; Rosen, Terry J.
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 59 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 610021	A1	19940810	EP 1994-300575	19940126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5340826	A	19940823	US 1993-13277	19930204
	US 5519033	A	19960521	US 1994-251493	19940531
PRAI	US 1993-13277	A	19930204		

AB Urinary incontinence is prevented or treated in mammals, including humans, by administration of certain quinuclidine derivs., piperidine derivs., azanorbornane derivs., ethylenediamine derivs., and related compds. which act as substance P receptor antagonists (no data). The preferred dosage range is 0.07-21 mg/kg orally or parenterally.

IT **136871-15-3**
RL: BIOL (Biological study)
(bladder incontinence treatment with)
RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:483063 CAPLUS
DN 121:83063
TI Preparation of 3-aminopiperidine derivatives and related nitrogen containing heterocycles for use in treatment of inflammatory and CNS disorders
IN Desai, Manoj C.; Rosen, Terry J.
PA Pfizer Inc., USA
SO U.S., 42 pp. Cont.-in-part of U.S. Ser. No. 619,361, abandoned.
CODEN: USXXAM
DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5232929	A	19930803	US 1991-724268	19910701
	CA 2111461	AA	19930121	CA 1992-2111461	19920521
	CA 2111461	C	19961217		
	WO 9301170	A1	19930121	WO 1992-US4008	19920521
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	EP 594636	A1	19940504	EP 1992-911581	19920521
	EP 594636	B1	19980121		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 06508828	T2	19941006	JP 1992-511510	19920521
	JP 2531565	B2	19960904		
	AT 162521	E	19980215	AT 1992-911581	19920521
	ES 2111639	T3	19980316	ES 1992-911581	19920521
	US 5332817	A	19940726	US 1993-14970	19930208
PRAI	US 1990-619361	B2	19901128		
	US 1991-724268	A	19910701		
	WO 1992-US4008	W	19920521		

OS MARPAT 121:83063

GI For diagram(s), see printed CA Issue.

AB Title compds. I [Y = (CH2)n n = 1-6; any one of C-C in (CH2)n may be replaced by C-C double bond; (un)substituted R4, R7 = H, HO, halo, amino, O, etc.; m = 0-8, R8 = HON:, etc.; R1 = H, (substituted) C1-8 alkyl; R2 = H, C1-6 alkyl, (substituted) C3-7 cycloalkyl, Ph, naphthyl, heterocyclyl, phenyl-C2-6 alkyl, etc.; R5 = H, Ph, C1-6 alkyl; R2R5C = (substituted) C3-7 carbocyclyl; R3 = Ph, naphthyl, heterocyclyl, etc.; R6 = R9CONH, R9CH2NH, R9O2S wherein R9 = C1-6 alkyl, H, Ph, Ph-C1-6-alkyl with provisos] or as pharmaceutically acceptable salts, useful in treatment of inflammatory and CNS disorders (no data), are prepared 2-Oxo-5-hydroxyimino-6-phenylpiperidine (preparation given) in EtOH was hydrogenated in the presence of Raney Ni to give a mixture of cis- and trans-5-amino-2-oxo-6-phenylpiperidine to which was added 2-methoxybenzaldehyde/sodium cyanoborohydride to give cis-5-(2-methoxybenzylamino)-2-oxo-6-phenylpiperidine which was treated with borane dimethylsulfide to give benzylaminopiperidine cis-II.

IT **136920-93-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and reaction. of, in preparation of drug for treatment of inflammation and CNS disorders)

RN 136920-93-9 CAPLUS

CN 2-Piperidinone, 5-[[(2-methoxyphenyl)methyl]amino]-4,6-diphenyl- (9CI) (CA INDEX NAME)



IT **136871-15-3P 136898-70-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, for treatment of inflammation and CNS disorders)

RN 136871-15-3 CAPLUS

CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



RN 136898-70-9 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

L4 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:632089 CAPLUS
DN 115:232089
TI 3-Aminopiperidine derivatives and related nitrogen-containing heterocycles
IN Desai, Manoj C.; Rosen, Terry J.
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 67 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 436334	A2	19910710	EP 1990-313680	19901214
	EP 436334	A3	19920527		
	EP 436334	B1	19941207		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 9109844	A1	19910711	WO 1990-US116	19900104
	W: FI, HU, NO, RO, SU, US				
	EP 558156	A2	19930901	EP 1993-201034	19901214
	EP 558156	A3	19931006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ES 2064667	T3	19950201	ES 1990-313680	19901214
	JP 04103570	A2	19920406	JP 1990-409476	19901228
	JP 07057748	B4	19950621		
	IL 96821	A1	19970318	IL 1990-96821	19901228
	IL 112348	A1	19980615	IL 1990-112348	19901228
	CA 2033497	AA	19910705	CA 1991-2033497	19910102
	CA 2033497	C	19970107		
	AU 9168621	A1	19910718	AU 1991-68621	19910102

	AU 625511	B2	19920716		
	HU 60719	A2	19921028	HU 1991-6	19910102
	PL 163967	B1	19940630	PL 1991-288592	19910102
	PL 164203	B1	19940630	PL 1991-293390	19910102
	PL 164204	B1	19940630	PL 1991-293391	19910102
	PL 164205	B1	19940630	PL 1991-293392	19910102
	PL 164244	B1	19940729	PL 1991-293389	19910102
	HU 68130	A2	19950529	HU 1992-3403	19910102
	HU 68180	A2	19950529	HU 1992-3404	19910102
	HU 68179	A2	19950529	HU 1992-3405	19910102
	FI 9100034	A	19910705	FI 1991-34	19910103
	FI 114096	B1	20040813		
	NO 9100016	A	19910705	NO 1991-16	19910103
	NO 178187	B	19951030		
	NO 178187	C	19960207		
	CN 1053060	A	19910717	CN 1991-100039	19910103
	CN 1035944	B	19970924		
	BR 9100016	A	19911022	BR 1991-16	19910103
	ZA 9100036	A	19920826	ZA 1991-36	19910103
	CZ 289485	B6	20020213	CZ 1991-10	19910104
	RU 2105758	C1	19980227	RU 1991-5010406	19911223
	CN 1087083	A	19940525	CN 1993-116286	19930820
	CN 1045595	B	19991013		
	FI 2004000479	A	20040401	FI 2004-479	20040401
PRAI	WO 1990-US116	A	19900104		
	EP 1990-313680	A	19901214		
	IL 1990-96821	A3	19901228		
	HU 1991-6	A	19910102		

OS MARPAT 115:232089

GI



I

AB Title compds., e.g., I (n = 1, 2; R = H, 2-OMe; R = Ph, CHPh2), were prepared for treatment of inflammatory, central nervous system, and other disorders. Thus, 2-oxo-5-oximino-6-phenylpiperidine was hydrogenated over Raney Ni in EtOH-MeOH to give cis- and trans-5-amino-2-oxo-6-phenylpiperidine, which reacted with NaBH3CN and 2-MeOC6H4CHO in HCl-MeOH containing 4-Å sieves to give cis-5-[(2-methoxybenzyl)amino]-2-oxo-6-phenylpiperidine (II). Reduction of II with BH3·SMe2 in THF gene cis-I (n = 1, R = 2-OMe, R1 = Ph) as the HCl salt in 96% yield.

IT **136920-93-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 136920-93-9 CAPLUS

CN 2-Piperidinone, 5-[[(2-methoxyphenyl)methyl]amino]-4,6-diphenyl- (9CI) (CA INDEX NAME)



IT **136898-70-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 136898-70-9 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT **136871-15-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as pharmaceutical)
RN 136871-15-3 CAPLUS
CN 3-Piperidinamine, N-[(2-methoxyphenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)